For immediate release 2.00pm: 28 April 2016
HVIVO PLC
("hVIVO" or the "Company")
2015 Annual Report and Financial Statements
hVIVO plc (AIM: HVO), the pioneer of human models of disease, is pleased to announce that its Annual Report and Financial Statements for the year ended 31 December 2015 is being posted to shareholders today. It will be available on the Company's website (http://hvivo.com/investors/financial-reports/) from 4.30 pm today.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, RSV, asthma and common cold. hVIVO has commercialised four disease models, successfully enrolled over 2,000 subjects and conducted over 40 product validation studies for a wide range of industry, government and academic clients and collaborators.
